Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
Conduit Pharmaceuticals (Nasdaq: CDT) has entered into a strategic services agreement with Agility Life Sciences to develop new solid oral-dosage forms for its autoimmune pipeline. Agility, known for its drug formulation expertise, will help Conduit create enhanced oral dosage forms for future clinical trials. These formulations are protected by new composition-of-matter intellectual property (IP) and aim to meet patient preferences and disease-specific needs.
The collaboration will leverage Agility's extensive formulation knowledge to maximize the market potential of Conduit's assets. Conduit's pipeline includes several Phase 2-ready candidates with clinically tested oral formulations, enabling efficient progression into Phase 2 trials. This dual-track approach of ongoing clinical trials and formulation development aims to strengthen market protection, enhance market value, and optimize future licensing opportunities.
Conduit Pharmaceuticals (Nasdaq: CDT) ha stipulato un accordo di servizi strategici con Agility Life Sciences per sviluppare nuove forme di dosaggio orale solido per il suo pipeline autoimmune. Agility, nota per la sua esperienza nella formulazione di farmaci, aiuterà Conduit a creare forme di dosaggio orale migliorate per i futuri studi clinici. Queste formulazioni sono protette da nuove proprietà intellettuali relative alla composizione del prodotto (IP) e mirano a soddisfare le preferenze dei pazienti e le esigenze specifiche della malattia.
La collaborazione sfrutterà l'ampia conoscenza di Agility nella formulazione per massimizzare il potenziale di mercato degli asset di Conduit. Il pipeline di Conduit include diversi candidate pronti per la Fase 2 con formulazioni orali testate clinicamente, consentendo una progressione efficiente verso gli studi di Fase 2. Questo approccio a doppio binario di studi clinici in corso e sviluppo di formulazioni mira a rafforzare la protezione del mercato, aumentare il valore di mercato e ottimizzare le future opportunità di licenza.
Conduit Pharmaceuticals (Nasdaq: CDT) ha firmado un acuerdo de servicios estratégicos con Agility Life Sciences para desarrollar nuevas formas de dosificación oral sólida para su pipeline de enfermedades autoinmunes. Agility, conocida por su experiencia en formulación de medicamentos, ayudará a Conduit a crear formas de dosificación oral mejoradas para futuros ensayos clínicos. Estas formulaciones están protegidas por nueva propiedad intelectual relacionada con la composición del producto (IP) y tienen como objetivo satisfacer las preferencias de los pacientes y las necesidades específicas de la enfermedad.
La colaboración aprovechará el amplio conocimiento de Agility en formulación para maximizar el potencial de mercado de los activos de Conduit. El pipeline de Conduit incluye varios candidatos listos para la Fase 2 con formulaciones orales probadas clínicamente, lo que permite una progresión eficiente hacia los ensayos de Fase 2. Este enfoque dual de ensayos clínicos en curso y desarrollo de formulaciones busca fortalecer la protección del mercado, aumentar el valor de mercado y optimizar futuras oportunidades de licencia.
Conduit Pharmaceuticals (Nasdaq: CDT)는 자가면역 파이프라인을 위한 새로운 고형 경구용 제형 개발을 위해 Agility Life Sciences와 전략적 서비스 계약을 체결했습니다. 약물 제형 전문으로 알려진 Agility는 Conduit가 향후 임상 시험을 위한 경구용 제형을 개선하는 데 도움을 줄 것입니다. 이러한 제형은 새로운 물질 조성에 대한 지적 재산권(IP)에 의해 보호되며 환자의 선호와 질병-specific 요구를 충족할 수 있도록 설계되었습니다.
이번 협력은 Agility의 광범위한 제형 지식을 활용하여 Conduit의 자산의 시장 잠재력을 극대화할 것입니다. Conduit의 파이프라인에는 임상적으로 시험된 경구 제형을 가진 여러 개의 2상 후보가 포함되어 있어 2상 시험으로의 효율적인 진행이 가능합니다. 지속적인 임상 시험과 제형 개발의 이중 경로 접근 방식은 시장 보호를 강화하고 시장 가치를 높이며 미래의 라이센스 기회를 최적화하는 것을 목표로 합니다.
Conduit Pharmaceuticals (Nasdaq: CDT) a conclu un accord de services stratégiques avec Agility Life Sciences pour développer de nouvelles formes de dosage oral solide pour son pipeline de maladies auto-immunes. Agility, reconnue pour son expertise en formulation de médicaments, aidera Conduit à créer des formes de dosage oral améliorées pour les futurs essais cliniques. Ces formulations sont protégées par de nouveaux droits de propriété intellectuelle sur la composition (IP) et visent à répondre aux préférences des patients et aux besoins spécifiques des maladies.
Cette collaboration tirera parti des vastes connaissances d’Agility en matière de formulation pour maximiser le potentiel de marché des actifs de Conduit. Le pipeline de Conduit comprend plusieurs candidats prêts pour la Phase 2 avec des formulations orales testées cliniquement, permettant une progression efficace vers les essais de Phase 2. Cette approche à double voie, avec des essais cliniques en cours et le développement de formulations, vise à renforcer la protection du marché, à accroître la valeur marchande et à optimiser les futures opportunités de licence.
Conduit Pharmaceuticals (Nasdaq: CDT) hat eine strategische Dienstleistungsvereinbarung mit Agility Life Sciences geschlossen, um neue feste orale Darreichungsformen für seine Autoimmunpipeline zu entwickeln. Agility, bekannt für seine Expertise in der Arzneimittel-Formulierung, wird Conduit unterstützen, verbesserte orale Darreichungsformen für zukünftige klinische Studien zu erstellen. Diese Formulierungen sind durch neue geistige Eigentumsrechte zur Zusammensetzung des Produkts (IP) geschützt und zielen darauf ab, die Patientenpräferenzen und krankheitsspezifischen Bedürfnisse zu erfüllen.
Die Zusammenarbeit wird Agilitys umfassendes Fachwissen in der Formulierung nutzen, um das Marktpotenzial von Conduits Vermögenswerten zu maximieren. Conduits Pipeline umfasst mehrere Kandidaten, die für Phase 2 bereit sind und klinisch getestete orale Formulierungen aufweisen, was einen effizienten Übergang zu Phase 2-Studien ermöglicht. Dieser duale Ansatz aus laufenden klinischen Studien und Formulierungsentwicklung soll den Marktschutz stärken, den Marktwert erhöhen und zukünftige Lizenzmöglichkeiten optimieren.
- Strategic partnership with Agility Life Sciences to enhance oral dosage forms.
- New formulations protected by robust composition-of-matter IP.
- Pipeline includes Phase 2-ready candidates with clinically tested formulations.
- Efficient progression into Phase 2 trials using existing data packages.
- Potential to maximize market value and optimize future licensing opportunities.
- None.
Insights
The strategic partnership between Conduit Pharmaceuticals and Agility Life Sciences marks a sophisticated approach to pharmaceutical development that could significantly enhance Conduit's market position. The focus on developing new solid oral-dosage formulations, protected by composition-of-matter IP, is particularly noteworthy as this type of intellectual property provides the strongest form of protection in the pharmaceutical industry.
The dual-track development strategy is especially clever: while advancing existing formulations into Phase 2 trials to maintain development momentum, Conduit simultaneously works on enhanced formulations. This approach could create substantial value through: 1) Improved patient compliance through better formulations, 2) Extended market exclusivity through new patents and 3) Enhanced licensing opportunities with potential pharma partners.
For investors, this partnership represents a risk-mitigation strategy. The company can proceed with clinical trials using proven formulations while developing potentially superior versions, essentially creating a backup plan that could also serve as an upside catalyst. The focus on solid oral dosage forms is particularly strategic for autoimmune conditions, where long-term treatment adherence is important for patient outcomes.
This strategic collaboration reveals Conduit's sophisticated approach to maximizing asset value in the competitive autoimmune therapeutics market. By partnering with Agility Life Sciences, a proven formulation development CDMO, Conduit is executing a two-pronged strategy that balances immediate development progress with long-term value creation.
The business implications are significant: 1) Enhanced formulations could command premium pricing in the market, 2) Stronger IP protection through new composition-of-matter patents could extend market exclusivity and 3) Improved formulations could provide competitive differentiation in the crowded autoimmune space.
For a company with a
- Award-winning Agility Life Sciences brings a proven track record in drug formulation for a number of pharmaceutical and biotechnology clients.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced that it has entered into a strategic services agreement with formulation development CDMO Agility Life Sciences (“Agility”) to develop new solid oral-dosage form products of its autoimmune pipeline for use in future clinical trials.
Conduit has developed a series of novel, advantageous solid forms of all its autoimmune pipeline assets, each protected by newly established composition-of-matter intellectual property (IP). Leveraging Agility’s extensive formulation expertise, Conduit believes this collaboration will focus on utilizing these proprietary forms to develop enhanced oral dosage forms for each asset. These dosage forms, designed with patient preferences and disease-specific needs in mind, are intended to allow Conduit to maximize the market potential of each asset while being underpinned by robust composition of matter IP.
As part of its focus on acquiring Phase 2-ready assets, Conduit’s pipeline includes several candidates that already have clinically tested oral formulations. This enables the Company to efficiently advance into Phase 2 trials using existing data packages. In parallel with ongoing autoimmune clinical trial plans, Conduit will work with Agility to develop enhanced proprietary oral dosage formulations for each asset. This dual-track approach is intended to strengthen market protection, enhance market value, and optimize the positioning of each asset for future licensing opportunities.
About Agility Life Sciences
Agility is an award-winning formulation development CDMO that turns molecules into smart formulations which maximizes the probability of success in pre-clinical studies to enable them to be accelerated in clinical, by evaluating the successful end-result before embarking on projects. Agility develop and manufacture formulations for various routes of administration including oral, ocular, IV, intranasal and topical to meet the needs of their clients.
About Conduit Pharmaceuticals
Conduit is a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets and then seeks an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks as identified in filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.
Investors & Media:
Info@conduitpharma.com
FAQ
What is Conduit Pharmaceuticals' new partnership about?
What does the CDT and Agility collaboration mean for clinical trials?
How will the new formulations impact Conduit Pharmaceuticals' market potential?
What stage are Conduit Pharmaceuticals' autoimmune candidates in?
How does the partnership with Agility Life Sciences benefit Conduit Pharmaceuticals' licensing opportunities?
